Arvest Trust Co. N A Decreases Position in Pfizer Inc. (NYSE:PFE)

Arvest Trust Co. N A cut its stake in shares of Pfizer Inc. (NYSE:PFE) by 3.4% during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 485,907 shares of the biopharmaceutical company’s stock after selling 17,344 shares during the period. Arvest Trust Co. N A’s holdings in Pfizer were worth $13,596,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Gilbert & Cook Inc. boosted its holdings in Pfizer by 3.8% in the fourth quarter. Gilbert & Cook Inc. now owns 25,651 shares of the biopharmaceutical company’s stock valued at $738,000 after purchasing an additional 945 shares during the last quarter. Gryphon Financial Partners LLC boosted its stake in Pfizer by 43.7% during the 4th quarter. Gryphon Financial Partners LLC now owns 26,942 shares of the biopharmaceutical company’s stock valued at $861,000 after acquiring an additional 8,194 shares during the last quarter. Sachetta LLC acquired a new position in Pfizer during the 4th quarter worth $134,000. Corient Private Wealth LLC increased its position in shares of Pfizer by 8.8% in the 4th quarter. Corient Private Wealth LLC now owns 3,442,834 shares of the biopharmaceutical company’s stock worth $99,119,000 after purchasing an additional 279,095 shares during the last quarter. Finally, Quest Partners LLC bought a new position in shares of Pfizer during the fourth quarter worth about $186,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

Shares of NYSE PFE opened at $30.07 on Tuesday. Pfizer Inc. has a 12-month low of $25.20 and a 12-month high of $34.12. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65. The company has a market cap of $170.40 billion, a PE ratio of -501.08, a P/E/G ratio of 1.02 and a beta of 0.68. The stock has a 50 day simple moving average of $29.26 and a 200-day simple moving average of $28.15.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.46 by $0.14. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The company had revenue of $13.28 billion during the quarter, compared to analysts’ expectations of $12.96 billion. During the same quarter in the prior year, the business posted $0.67 earnings per share. The company’s revenue for the quarter was up 2.1% compared to the same quarter last year. On average, equities research analysts forecast that Pfizer Inc. will post 2.66 EPS for the current year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th were paid a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.59%. The ex-dividend date was Friday, July 26th. Pfizer’s dividend payout ratio is currently -2,799.53%.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the company. Daiwa Capital Markets raised Pfizer from a “neutral” rating to an “outperform” rating and boosted their price objective for the company from $28.00 to $34.00 in a report on Wednesday, August 7th. Daiwa America upgraded Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. UBS Group raised their price objective on Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 31st. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research note on Monday. Finally, StockNews.com raised shares of Pfizer from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Eight research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $34.54.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.